ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer

Journal of the National Cancer Institute

Volumn 95, Issue 11, 2003, Pages 818-824

  Severi, Gianluca ^a   Giles, Graham G ^b   Southey, Melissa C ^c   Tesoriero, Andrea ^c   Tilley, Wayne ^d   Neufing, Howard ^d   Morris, Howard ^e   English, Dallas R ^b   McCredie, Margaret R E ^f   Boyle, Peter ^a   Hopper, John L ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b CANCER EPIDEMIOLOGY CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e HANSON INSTITUTE   (Australia)

^f UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ELAC2 PROTEIN; LEUCINE; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; SERINE; THREONINE; UNCLASSIFIED DRUG; ELAC2 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AUSTRALIA; BLOOD LEVEL; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DATA ANALYSIS; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

AGED; ALANINE; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LEUCINE; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ODDS RATIO; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SERINE; THREONINE;

EID: 0038042075     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.11.818     Document Type: Article

References (20)

1. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-504.
2. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 1995;55:3973-5.
3. Durocher F, Shattuck-Eidens D, McClure M, Labrie F, Skolnick MH, Goldgar DE, et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet 1996;5:835-42.
4. Huttley GA, Easteal S, Southey MC, Tesoriero A, Giles GG, McCredie MR, et al. Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study. Nat Genet 2000; 25:410-3.
5. Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000;26:362-4.
6. Spurdle AB, Hopper JL, Chen X, Dite GS, Cui J, McCredie MR, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev 2002;11:413-6.
7. Tavtigian SV, Simard J, Labrie F, Skolnick M, Neuhausen SL, Rommens J, et al. A strong candidate prostate cancer predisposition gene at chromosome 17p. Am J Hum Genet 2000;67(suppl):11.
8. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27:172-80.
9. Rebbeck TR, Walker AH, Zeiger-Johnson C, Weisburg S, Martin AM, Nathanson KL, et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67:1014-9.
10. Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, et al. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 2001;61:4982-4.
11. Vesprini D, Nam RK, Tratchenberg J, Jewett AS, Tavtigian AV, Emami M, et al. HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 2001;68:912-7.
12. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001;68: 901-11.
13. Rökman A, Ikonen T, Monen N, Autio V, Matikaiunen MP, Koivisto PA, et al. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res 2001;61:6038-41.
14. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, et al. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001;61:6494-9.
15. Giles GG, Severi G, Sinclair G, English DR, McCredie MR, Johnson W, et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 2002;11: 549-53.
16. Sham P. Statistics in human genetics. London (UK): Arnold; 1998. p. 39-50.
17. Hosmer DW, Lemeshow S. Applied logistic regression. New York (NY): Wiley; 1989.
18. Rothman K, Greenland S. Modern epidemiology. Philadelphia (PA): Lippincott-Raven; 1998. p. 658-64.
19. S-plus 2000: user's guide. Seattle (WA): Mathsoft, Data Analysis Products Division; 1999.
20. Freely associating. Nat Genet 1999;22:1-2.